Dental Care Clinics in Barceloneta, PR Accepting Medicare
3 Dental Care Clinics found. Showing 1 - 3
 Atlantic Medical Center Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: Box 2045, Barceloneta, PR 00617 Phone: 787-846-4412 Fax: 787-846-7410 |
Barceloneta Dental Group Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1 Calle Tomas Davila, Barceloneta, PR 00617 Phone: 787-846-0331 Fax: 787-846-0331 |
Viruet Dentistry Llc Clinic/Center - Dental Medicare: Medicare Enrolled Practice Location: Carr #2 Km 55.5 Sector Palenque, Barceloneta, PR 00617 Phone: 787-846-0352 |
News Archive
Researchers reveal how rapidly spreading ovarian cancer cells take the next steps
In nearly 80 percent of women with ovarian cancer, the disease has already spread to the omentum before it was diagnosed. Within the omentum -; a large, energy-dense fat pad that covers the intestines -; the cancer grows even faster.
New insights into brain cell metabolism from PET and MRI scans
By discovering a crucial piece of submicroscopic information about how the brain converts fuel into energy for neurons, Cornell University biophysicists have gleaned new insights into brain cell metabolism that will allow neurologists to better interpret data from such diagnostic tests as positron emission tomography (PET) scans and a specialized magnetic resonance imaging (MRI) test.
FDA clears DFine's new percutaneous radiofrequency ablation device for metastatic spinal lesions
DFine, Inc., developer of minimally invasive solutions for the treatment of vertebral pathologies, announced today the 510(k) clearance of a new platform extension indicated for the palliative treatment of cancer patients. The product, a percutaneous radiofrequency ablation (RFA) device, provides localized tumor necrosis of vertebral body lesions where metastatic disease has spread to the spine causing severe pain and discomfort.
Bavarian Nordic completes last step to support use of IMVAMUNE, receives FDA notification
Bavarian Nordic A/S announced today that it has received notification that the U.S. Food and Drug Administration (FDA) has accepted all the actions taken by the company to address the observations made during the inspection of the manufacturing facilities in 2009. This was the last step along with the clinical and preclinical data that will be used to potentially support the use of IMVAMUNE® following a declared emergency.
Newly-developed epigenetic test can be used to identify tumors responsible for metastasis in cancer patient
In patients with cancer, initial diagnosis most often includes the detection of the primary or original tumor and the presence or absence of metastases, ie cells from the original tumor that have escaped from their original location and are growing into other tissues of the patient.
› Verified 3 days ago